Disease-modifying drug combination targeting KAT-7 and HIF-2alpha formulated using active targeted dendrimer with enhanced cartilage penetration and retention for osteoarthritis treatment.
Implementing Organization
Indian Institute of Technology (IIT)
Principal Investigator
Dr. Dhirendra s Katti
Indian Institute of Technology (IIT)
CO-Principal Investigator
Dr. Amitabha Bandyopadhyay
Indian Institute of Technology (IIT)
About
Osteoarthritis (OA) is a complex joint disorder affecting over 500 million people worldwide. Current treatments only alleviate symptoms without modifying the disease, and surgeries are associated with secondary complications. To develop disease-modifying approaches, researchers have identified KAT-7, a protein that helps the survival of senescent cells in Werner syndrome, as a potential target. They hypothesized that KAT-7 might be present in OA cartilage and used a specific inhibitor (WM-3835) to downregulate senescence in the goat OA model and human OA cartilage. A HIF2alpha-specific inhibitor (PT-2385) was also identified to downregulate other OA hallmarks. The combination of inhibitors will be studied in a goat ex vivo OA model and human OA cartilage explants to demonstrate enhanced OA mitigation. Implementation of this proposal could lead to a paradigm shift in OA disease modification.
Source
Source
science and Engineering Research Board (sERB), DsT
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.